Cat. #152606
Anti-TNFRSF18 (soluble form) [T10P2H9*B9]
Cat. #: 152606
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: Tumor Necrosis Factor Receptor Superfamily, Member 18 (TNFRSF18-soluble form), GITR
Class: Monoclonal
Application: ELISA ; IHC ; WB
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Ayham Alnabulsi
Institute: Vertebrate Antibodies Limited
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-TNFRSF18 (soluble form) [T10P2H9*B9]
- Alternate name: Tumor Necrosis Factor Receptor Superfamily Member 18; Glucocorticoid-Induced TNFR-Related Protein; Activation-Inducible TNFR Family Receptor; AITR; GITR; TNF Receptor Superfamily Activation-Inducible Protein; CD357 Antigen; GITR-D; CD357
- Research fields: Cancer;Cell signaling and signal transduction;Immunology
- Clone: T10P2H9*B9
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 26 kDa
- Reactivity: Human
- Host: Mouse
- Application: ELISA ; IHC ; WB
- Description: TNFRSF18 is a type I transmembrane protein with homology to members of divergent costimulatory molecules in the TNFRSF. To date three isoforms of TNFRSF18 have been identified, including one soluble form that lacks a transmembrane domain. According to homology of the cytoplasmic domain, TNFRSF18 and other three TNFRSF members (4ÄËĂÂĂÂ1BB, CD27, and OX40) probably constitute a new subfamily as divergent costimulators. TNFRSF18 and the other subfamily members bind TRAF molecules and activate NF-KB.
- Immunogen: Ovalbumin conjugated peptide - PWQQKWVQE
- Isotype: IgG1 kappa
- Recommended controls: IHC- formalin-fixed, paraffin-embedded breast cancer sections; WB - Jurkat cell lysates
Target Details
- Target: Tumor Necrosis Factor Receptor Superfamily, Member 18 (TNFRSF18-soluble form), GITR
- Molecular weight: 26 kDa
- Tissue cell line specificity: IHC- formalin-fixed, paraffin-embedded breast cancer sections; WB - Jurkat cell lysates
- Target background: TNFRSF18 is a type I transmembrane protein with homology to members of divergent costimulatory molecules in the TNFRSF. To date three isoforms of TNFRSF18 have been identified, including one soluble form that lacks a transmembrane domain. According to homology of the cytoplasmic domain, TNFRSF18 and other three TNFRSF members (41BB, CD27, and OX40) probably constitute a new subfamily as divergent costimulators. TNFRSF18 and the other subfamily members bind TRAF molecules and activate NF-KB.
Applications
- Application: ELISA ; IHC ; WB
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Dry ice
Related Tools
- Related tools: Anti-TNFRSF18(r) [T9P4G4*D7] ; Anti-TNFRSF18 (soluble form), Recombinant [T10P2H9*B9]
![Anti-TNFRSF18 (soluble form) [T10P2H9*B9]](https://cancertools.org/wp-content/uploads/e3be1b6f-b2d7-4be4-9bf3-a6b2117e6200.jpg)
![Anti-TNFRSF18 (soluble form) [T10P2H9*B9] - Image 2](https://cancertools.org/wp-content/uploads/47f459dc-7a1a-4505-bfc4-cf807cf6896f.png)
![Anti-TNFRSF18 (soluble form) [T10P2H9*B9] - Image 3](https://cancertools.org/wp-content/uploads/42736e42-69c0-4262-af56-b505d8e70950.jpg)
![Anti-TNFRSF18 (soluble form) [T10P2H9*B9] - Image 4](https://cancertools.org/wp-content/uploads/20fe1e19-fc14-4b1d-b9cd-dc2d9bfb7fd9.png)


![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)



